Citius Oncology, Inc. CTOR Ratios & Valuation
| TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -119.9%— | -47.4%— | -54.4%— | -107.5%— | —— | |
| Liquidity | ||||||
| Current ratio | 0.5×+0.1× | 0.8×+0.4× | 0.6×+0.2× | 0.3×+0.3× | 0.4×+0.3× | |
| Per Share | ||||||
| Book value per share | $0.35-29.2% | $0.67+15.7% | $0.61-9.7% | $0.45+79.5% | $0.50+69.4% | |
| Valuation | ||||||
| Market capitalization | $60.45M-74.7% | $84.8M— | $169.53M— | —— | —— | |
| Price / book | 1.8×-5.9× | 1.5×— | 3.8×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Citius Oncology, Inc.'s ratios come from?
- Every ratio is computed from Citius Oncology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.